233 related articles for article (PubMed ID: 1703322)
1. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
Javaherian K; Langlois AJ; LaRosa GJ; Profy AT; Bolognesi DP; Herlihy WC; Putney SD; Matthews TJ
Science; 1990 Dec; 250(4987):1590-3. PubMed ID: 1703322
[TBL] [Abstract][Full Text] [Related]
2. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
3. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
4. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
Nkengasong JN; Peeters M; Ndumbe P; Janssens W; Willems B; Fransen K; Ngolle M; Piot P; van der Groen G
AIDS; 1994 Aug; 8(8):1089-96. PubMed ID: 7986404
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
6. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
[TBL] [Abstract][Full Text] [Related]
7. Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1).
Montero M; Menéndez A; Domínguez MC; Navea L; Vilarubia OL; Quintana D; Izquierdo M; Jiménez V; Reyes O; Lobaina L; Noa E; Duarte CA
Vaccine; 1997 Aug; 15(11):1200-8. PubMed ID: 9286044
[TBL] [Abstract][Full Text] [Related]
8. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
[TBL] [Abstract][Full Text] [Related]
9. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
10. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
[TBL] [Abstract][Full Text] [Related]
11. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).
Böttiger B; Karlsson A; Andreasson PA; Naucler A; Costa CM; Biberfeld G
AIDS Res Hum Retroviruses; 1989 Oct; 5(5):525-33. PubMed ID: 2590556
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
Berman PW; Matthews TJ; Riddle L; Champe M; Hobbs MR; Nakamura GR; Mercer J; Eastman DJ; Lucas C; Langlois AJ
J Virol; 1992 Jul; 66(7):4464-9. PubMed ID: 1602554
[TBL] [Abstract][Full Text] [Related]
13. Variable and conserved neutralization antigens of human immunodeficiency virus.
Weiss RA; Clapham PR; Weber JN; Dalgleish AG; Lasky LA; Berman PW
Nature; 1986 Dec 11-17; 324(6097):572-5. PubMed ID: 2431324
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
White-Scharf ME; Potts BJ; Smith LM; Sokolowski KA; Rusche JR; Silver S
Virology; 1993 Jan; 192(1):197-206. PubMed ID: 7685962
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
16. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
17. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
19. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
